Levobupivacaína Kabi

Levobupivacaine, the active ingredient in Levobupivacaína Kabi, is a local anesthetic (amide) presented as a sterile solution for injection for epidural, infiltration, intrathecal and peripheral nerve block use. It provides surgical anesthesia and analgesia in adult patients undergoing operative or obstetric procedures.

GNH USA supplies Levobupivacaína Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Our distribution network ensures timely delivery across continents.

Levobupivacaine is a local anesthetic used to block nerve transmission in various surgical and analgesic settings. - Surgical anesthesia: provides complete loss of sensation during operative procedures. - Post‑operative analgesia: extends pain relief after surgery, reducing opioid requirements. - Labor analgesia: offers effective pain control during childbirth while preserving maternal consciousness. - Peripheral nerve block: produces targeted numbness for limb surgeries and diagnostic procedures.

Levobupivacaine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypotension: transient drop in blood pressure during administration. - Bradycardia: slowed heart rate, especially with high spinal or epidural doses. - Dizziness: sensation of light‑headedness or imbalance. - Nausea: upset stomach, sometimes with vomiting. - Metallic taste: transient alteration in taste perception. - Headache: mild to moderate headache after block.

Serious or Rare Side Effects: - Cardiac arrest: sudden loss of heart function, requiring immediate resuscitation. - Seizures: central nervous system excitation leading to convulsions. - Respiratory depression: reduced breathing effort that may need ventilatory support. - Anaphylaxis: severe allergic reaction with hives, swelling, and airway compromise. - Prolonged motor block: extended loss of muscle function beyond expected duration. - Methemoglobinemia: abnormal hemoglobin causing reduced oxygen delivery.

When using Levobupivacaine, clinicians should observe several precautionary measures to minimize risk. - Patient assessment: evaluate cardiovascular and respiratory status before administration. - Dose titration: adjust volume and concentration based on patient weight, age and procedure. - Contraindications: avoid use in individuals with known hypersensitivity to amide‑type local anesthetics. - Monitoring: continuously observe blood pressure, heart rate and oxygen saturation during and after injection. - Pregnancy considerations: safety in pregnancy and lactation is not well established; use only if benefit outweighs risk. - Store at ambient temperature: keep in original packaging, protect from light and moisture, and store below 25 °C.

Levobupivacaine can interact with other medicines, altering its safety profile or efficacy.

Major Interactions (Avoid): - Co‑administration with other local anesthetics: increases risk of systemic toxicity. - Concurrent CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation and respiratory depression. - Sodium channel blockers (e.g., quinidine, procainamide): potentiate cardiotoxic effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may exacerbate bradycardia and hypotension. - Calcium channel blockers: can affect cardiac conduction when combined. - MAO inhibitors: may increase risk of hypertension during regional anesthesia.